ArticlePloS one2018
Evaluation of preventable adverse drug reactions by implementation of the nationwide network of prospective drug utilization review program in Korea.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemiology and characteristics of repeat adverse drug reactions and associated clinical outcomes in older adults: a systematic review and meta-analysis.European geriatric medicine · 2026Pooled it
- PIVOT: Pharmacist Interventions for Value and Outcome Transformation in Specialty Pharmacy.Journal of managed care & specialty pharmacy · 2026Article
- How to leverage medication use evaluations for antimicrobial stewardship goals: a primer for physicians.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Review
- Updated guidelines for prescribing opioids to treat patients with chronic non-cancer pain in Korea: developed by committee on hospice and palliative care of the Korean Pain Society.The Korean journal of pain · 2024Article
- Shared Interoperable Clinical Decision Support Service for Drug-Allergy Interaction Checks: Implementation Study.JMIR medical informatics · 2022Article
- Drug Utilization Evaluation (DUE) of vancomycin: A cross-sectional study.Annals of medicine and surgery (2012) · 2022Article
- Nationwide prevalence of potential drug-drug interactions associated with non-anticancer agents in patients on oral anticancer agents in South Korea.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Improving drug safety in hospitals: a retrospective study on the potential of adverse drug events coded in routine data.BMC health services research · 2019Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA prospective Drug Utilization Review (DUR) program has been implemented in Korea to improve the quality and safety of medication use.
objectiveTo evaluate the influence of the DUR program in reducing incidence of preventable adverse drug reactions (pADRs).
methodsThis study was performed using administrative data from the Health Insurance Review and Assessment Service (HIRA). The claims data for all adult patients with adverse drug events (ADE)-related diagnoses from 2009 to 2014 were obtained. Incidence rates of first-time and repeat pADRs prior to and after DUR program implementation were evaluated. Quarterly trends in incidence rates of overall ADE, allergic reactions, and ADRs were analyzed.
resultsData extraction covering the period from 2009 to 2014 led to the identification of 3,927,662 records. First-time pADR rates decreased gradually after implementation of the DUR program (change in slope: -0.016, p = 0.02). The program had a similar influence on repeat pADR rates (change in slope: -0.006, p≤0.01). The program did not decrease rates of first-time or repeat allergic reactions (change in slope: 0.018, p = 0.07 and 0.003, p = 0.04, respectively). In the cohort aged ≤65 years, first-time pADR rate reduction was significant (28.2% [27.1-29.3] in ≤18 years, and 19.8% [18.1-21.5] in 19-64 years). In contrast, first-time pADR rate was increased by 0.6% [-0.7-1.9] in patients ≥65 years.
conclusionImplementation of the prospective DUR program effectively reduced the number of pADRs. In the future, to reduce non-preventable ADRs such as allergic reactions, provision of clinical information including allergy history should be added to the DUR program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.